DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study
Glenn E Palomaki, Cosmin Deciu, Edward M Kloza, Geralyn M Lambert-Messerlian, James E Haddow, Louis M Neveux, Mathias Ehrich, Dirk van den Boom, Allan T Bombard, Wayne W Grody, Stanley F Nelson, Jacob A Canick, Glenn E Palomaki, Cosmin Deciu, Edward M Kloza, Geralyn M Lambert-Messerlian, James E Haddow, Louis M Neveux, Mathias Ehrich, Dirk van den Boom, Allan T Bombard, Wayne W Grody, Stanley F Nelson, Jacob A Canick
Abstract
Purpose: To determine whether maternal plasma cell-free DNA sequencing can effectively identify trisomy 18 and 13.
Methods: Sixty-two pregnancies with trisomy 18 and 12 with trisomy 13 were selected from a cohort of 4,664 pregnancies along with matched euploid controls (including 212 additional Down syndrome and matched controls already reported), and their samples tested using a laboratory-developed, next-generation sequencing test. Interpretation of the results for chromosome 18 and 13 included adjustment for CG content bias.
Results: Among the 99.1% of samples interpreted (1,971/1,988), observed trisomy 18 and 13 detection rates were 100% (59/59) and 91.7% (11/12) at false-positive rates of 0.28% and 0.97%, respectively. Among the 17 samples without an interpretation, three were trisomy 18. If z-score cutoffs for trisomy 18 and 13 were raised slightly, the overall false-positive rates for the three aneuploidies could be as low as 0.1% (2/1,688) at an overall detection rate of 98.9% (280/283) for common aneuploidies. An independent academic laboratory confirmed performance in a subset.
Conclusion: Among high-risk pregnancies, sequencing circulating cell-free DNA detects nearly all cases of Down syndrome, trisomy 18, and trisomy 13, at a low false-positive rate. This can potentially reduce invasive diagnostic procedures and related fetal losses by 95%. Evidence supports clinical testing for these aneuploidies.
Figures
References
- Savva GM, Walker K, Morris JK. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome) Prenat Diagn. 2010;30:57–64.
- Data Access—Vital Statistics Online. Centers for Disease Control and Prevention . Accessed November 2011.
- Morris JK, Savva GM. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet A. 2008;146:827–832.
- Nembhard WN, Waller DK, Sever LE, Canfield MA. Patterns of first-year survival among infants with selected congenital anomalies in Texas, 1995–1997. Teratology. 2001;64:267–275.
- Rasmussen SA, Wong LY, Yang Q, May KM, Friedman JM. Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics. 2003;111:777–784.
- Palomaki GE, Haddow JE, Knight GJ,et al. Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin Prenat Diagn 199515713–723.
- Palomaki GE, Neveux LM, Knight GJ, Haddow JE. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. Prenat Diagn. 2003;23:243–247.
- Tul N, Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn. 1999;19:1035–1042.
- Ehrich M, Deciu C, Zwiefelhofer al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting Am J Obstet Gynecol 2011204205.e1–205.11.
- Palomaki GE, Kloza EM, Lambert-Messerlian al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study Genet Med 201113913–920.
- Chiu RW, Akolekar R, Zheng al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study BMJ 2011342c7401.
- Chiu RW, Chan KC, Gao al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma Proc Natl Acad Sci USA 200810520458–20463.
- Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA. 2008;105:16266–16271.
- Chiu RW, Sun H, Akolekar al. Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21 Clin Chem 201056459–463.
- Chen EZ, Chiu RW, Sun al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing PLoS ONE 20116e21791.
- Alkan C, Kidd JM, Marques-Bonet al. Personalized copy number and segmental duplication maps using next-generation sequencing Nat Genet 2009411061–1067.
- College of American Pathologists Surveys 2011, FP-A Maternal Screening 2011
- Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS) J Med Screen. 2003;10:56–104.
- Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21. Am J Obstet Gynecol. 2005;193:322–326.
- Palomaki GE, Knight GJ, Haddow JE, Canick JA, Saller DN, Jr, Panizza DS. Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotropin. Prenat Diagn. 1992;12:925–930.
- Haddow JE, Palomaki GE, Knight al. Prenatal screening for Down's syndrome with use of maternal serum markers N Engl J Med 1992327588–593.
- ACOG. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy Obstet Gynecol. 2007. pp. 1459–1467.
- Tabor A, Philip J, Madsen M, Bang J, Obel EB, Nørgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986;1:1287–1293.
Source: PubMed